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A bs tr ac t
Background
Recurrent stroke is a frequent, disabling event after ischemic stroke. This study com-
pared the efficacy and safety of two antiplatelet regimens — aspirin plus extended-
release dipyridamole (ASA–ERDP) versus clopidogrel.
Methods
In this double-blind, 2-by-2 factorial trial, we randomly assigned patients to receive 
25 mg of aspirin plus 200 mg of extended-release dipyridamole twice daily or to re-
ceive 75 mg of clopidogrel daily. The primary outcome was first recurrence of stroke. 
The secondary outcome was a composite of stroke, myocardial infarction, or death 
from vascular causes. Sequential statistical testing of noninferiority (margin of 1.075), 
followed by superiority testing, was planned.
Results
A total of 20,332 patients were followed for a mean of 2.5 years. Recurrent stroke 
occurred in 916 patients (9.0%) receiving ASA–ERDP and in 898 patients (8.8%) re-
ceiving clopidogrel (hazard ratio, 1.01; 95% confidence interval [CI], 0.92 to 1.11). The 
secondary outcome occurred in 1333 patients (13.1%) in each group (hazard ratio for 
ASA–ERDP, 0.99; 95% CI, 0.92 to 1.07). There were more major hemorrhagic events 
among ASA–ERDP recipients (419 [4.1%]) than among clopidogrel recipients (365 
[3.6%]) (hazard ratio, 1.15; 95% CI, 1.00 to 1.32), including intracranial hemorrhage 
(hazard ratio, 1.42; 95% CI, 1.11 to 1.83). The net risk of recurrent stroke or major 
hemorrhagic event was similar in the two groups (1194 ASA–ERDP recipients [11.7%], 
vs. 1156 clopidogrel recipients [11.4%]; hazard ratio, 1.03; 95% CI, 0.95 to 1.11).
Conclusions
The trial did not meet the predefined criteria for noninferiority but showed similar rates 
of recurrent stroke with ASA–ERDP and with clopidogrel. There is no evidence that ei-
ther of the two treatments was superior to the other in the prevention of recurrent 
stroke. (ClinicalTrials.gov number, NCT00153062.)
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Recurrent stroke is an important vascular event affecting the life of survivors of ischemic stroke.1 Multiple randomized 
trials have proved the efficacy of antiplatelet agents 
for the prevention of recurrent stroke after non-
cardioembolic stroke.2-11 Antiplatelet options for 
the prevention of recurrent stroke include aspirin 
(50 mg to 325 mg per day), the combination of low-
dose aspirin and extended-release dipyridamole, 
and clopidogrel alone.12,13
Aspirin has been shown to reduce the risk of 
stroke recurrence by about 23% as compared with 
placebo.7 Studies of clopidogrel have suggested an 
8% relative risk reduction of stroke recurrence, as 
compared with aspirin, among stroke patients, 
whereas studies of aspirin plus extended-release 
dipyridamole have suggested relative risk reduc-
tions of 20 to 23% as compared with aspirin 
alone.4,5,10,11 Indirect comparisons suggested that 
aspirin plus extended-release dipyridamole was 
superior to clopidogrel in the prevention of recur-
rent stroke.14
Although the combination of two antiplatelet 
agents with different mechanisms of action may 
be more effective in preventing recurrent stroke 
than either is alone, increased bleeding may result. 
Two trials have shown that the combination of 
aspirin and extended-release dipyridamole is bet-
ter than aspirin alone for prevention of recurrent 
stroke — as well as stroke, myocardial infarction, 
and death from vascular causes — without in-
creasing the risk of major bleeding.5,10,11 Among 
stroke patients with multiple risk factors, the ad-
dition of aspirin to clopidogrel is not more effica-
cious than clopidogrel alone but significantly 
increases the incidence of bleeding.8 Moderate 
bleeding is increased with the use of clopidogrel 
and aspirin, as compared with aspirin alone, in 
secondary and primary prevention.15,16
There is no guideline for using one of these 
therapies over the other.12,17 Thus, in this trial, we 
aimed to compare the relative efficacy and safety 
of aspirin plus extended-release dipyridamole with 
that of clopidogrel among patients who had a re-
cent ischemic stroke.18
Me thods
The Prevention Regimen for Effectively Avoiding 
Second Strokes (PRoFESS) trial was a 2-by-2 facto-
rial, double-blind, active and placebo-controlled 
study of the fixed combination of low-dose aspi-
rin (25 mg) and extended-release dipyridamole 
(200 mg) given twice daily as compared with clo-
pid ogrel (75 mg) given once daily, and of telmisar-
tan (80 mg once daily) as compared with placebo, 
in patients with a recent ischemic stroke. This ar-
ticle focuses on the antiplatelet comparison within 
the factorial design. The antiplatelet part of the 
factorial design was initially intended to compare 
clopidogrel plus aspirin with aspirin plus extended-
release dipyridamole. The design was modified, 
after 2027 patients were randomly assigned, when 
the Management of Atherothrombosis with Clo-
pid ogrel in High-Risk Patients with Recent TIA or 
Ischemic Stroke (MATCH) trial demonstrated an 
increased risk of bleeding with the combination 
of clopidogrel and aspirin.8 Patients initially as-
signed to receive clopidogrel plus aspirin had been 
treated for up to 8 months before they were 
switched to clopidogrel alone at the time of the 
protocol amendment; 18,305 patients were subse-
quently randomly assigned to receive aspirin plus 
extended-release dipyridamole or clopidogrel alone.
Details of the trial design have been published 
previously.18 The steering committee designed and 
oversaw the trial; data management was performed 
by the sponsor (Boehringer Ingelheim). A trial 
management committee, with representatives from 
the steering committee and the sponsor, met regu-
larly to evaluate progress. The cochairs and the 
members of the steering committee had complete 
access to the trial data and prepared the final 
manuscript, and they vouch for the design, the fi-
nal statistical analysis, and the completeness, ac-
curacy, and interpretation of the data. The final 
statistical analyses were conducted simultane-
ously by the independent statisticians at the 
Medical University of South Carolina (who pro-
vided data and interim analysis reports to the 
data and safety monitoring committee) and the 
statisticians from Boehringer Ingelheim.
The protocol was approved by the appropriate 
regulatory authorities and ethics committees or 
institutional review boards. All patients provided 
written informed consent.
Eligibility
The inclusion criteria were a recent ischemic stroke 
(within <90 days before randomization), defined 
by symptoms persisting for more than 24 hours or 
symptoms of a shorter duration but with evidence 
of a recent brain infarction on a computed tomo-
graphic scan or magnetic resonance imaging; 
clinical and neurologic stability before random-
ization; and an age of 55 years or older. Patients 
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were excluded if they had contraindications to one 
of the antiplatelet agents or were otherwise un-
suitable for randomization.18 After approximately 
6000 patients had been enrolled, a protocol amend-
ment was introduced to enhance recruitment and 
permit the inclusion of younger patients (50 to 54 
years of age) or those with less recent strokes 
(within 90 to 120 days before randomization) if 
they also had at least two additional vascular risk 
factors.18
Randomization and Treatment
Eligible and consenting patients were randomly 
assigned, through a central telephone randomiza-
tion system, to receive either aspirin (25 mg) plus 
extended-release dipyridamole (200 mg) twice daily 
or clopidogrel (75 mg daily) and telmisartan (80 mg 
daily) or placebo. Patients were evaluated in the 
hospital at the time of discharge or at 1 week after 
discharge and then at 1, 3, and 6 months and ev-
ery 6 months thereafter.
Outcome Events
The primary outcome was recurrent stroke of any 
type. The secondary outcome was a composite of 
stroke, myocardial infarction, or death from vas-
cular causes. The tertiary outcomes are listed in 
the Supplementary Appendix (available with the 
full text of this article at www.nejm.org). The pri-
mary and secondary outcomes, and episodes of 
major bleeding, were adjudicated by a central com-
mittee. If a patient had a recurrence of ischemic 
stroke, the Trial of Org 10172 in Acute Stroke 
Treatment (TOAST) criteria were used to classify 
the event.19 Three months after the recurrence of 
stroke, the degree of disability was assessed ac-
cording to the modified Rankin scale (with scores 
ranging from 0 to 6 and higher scores indicating 
greater disability) and the Barthel index (with 
scores ranging from 0 to 100 and higher scores 
indicating less disability).20,21 Definitions for hem-
orrhagic events (major, life-threatening, intracra-
nial, and minor) are listed in the Supplementary 
Appendix.
Data Monitoring
An independent data and safety monitoring com-
mittee regularly monitored the safety and quality 
of the data of the trial. Two formal interim effi-
cacy analyses were performed with the use of 
modified Haybittle–Peto22 boundaries to test the 
null hypotheses of no difference between treat-
ment groups, with thresholds of P<0.0001 when 
one third of expected events had occurred and 
P<0.001 when two thirds of the expected events 
had occurred.
Statistical Analysis
This event-driven trial was originally designed to 
test the superiority of aspirin plus extended-release 
dipyridamole over clopidogrel in 15,500 patients, 
modified to 20,000 patients after six protocol 
amendments owing to lower-than-expected num-
bers of primary outcome events. With this amend-
ed sample size, the trial had a statistical power of 
82% to detect a 13% relative risk reduction after 
1715 strokes had occurred.
A sequential analysis for the antiplatelet com-
parison was developed and planned to first test 
the noninferiority of aspirin plus extended-release 
dipyridamole as compared with clopidogrel. If this 
condition was satisfied, then the superiority of 
aspirin plus extended-release dipyridamole over 
clopidogrel could be assessed in a second test of 
the conventional null hypothesis of no difference 
between the two treatments.
Confirmation of noninferiority in this trial in-
volved the prespecification of a hazard ratio for 
aspirin plus extended-release dipyridamole, as 
compared with clopidogrel, that is below a pre-
defined margin. The margin was defined in the 
following way. Using data from the nonfatal stroke 
outcomes from the Clopidogrel versus Aspirin in 
Patients at Risk of Ischemic Events (CAPRIE) trial4 
and from the meta-analysis by the Antithrombotic 
Trialists’ Collaboration,7 and following the method 
of Fisher et al.,23 we derived an estimated odds 
ratio for clopidogrel being better than placebo for 
the outcome of nonfatal stroke: 1.377 (95% confi-
dence interval [CI], 1.155 to 1.645). Thus, to ensure 
that the aspirin plus extended-release dipyridamole 
preserved at least half the effect of clopidogrel, the 
noninferiority margin was set at 1.075, an effect 
size equal to half the lower limit of the confidence 
interval. To reject the inferiority null hypothesis, 
the upper boundary of the 95% confidence inter-
val for the hazard ratio must lie below the value of 
1.075 (an increase of 7.5% in the hazard associated 
with aspirin plus extended-release dipyridamole). 
With 1715 recurrent strokes, we would have a sta-
tistical power of 82% to reject the inferiority null 
hypothesis, assuming a 6.5% relative risk reduction 
with aspirin plus extended-release dipyridamole as 
compared with clopidogrel.
The primary analysis was of the time to the 
first recurrence of stroke. The Cox proportional-
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hazards regression model was prespecified for 
analysis of this outcome and had as covariates the 
baseline values for age, diabetes status, use or 
nonuse of angiotensin-converting–enzyme inhibi-
tors, and score on the modified Rankin scale. Be-
fore conducting the antiplatelet comparison, on 
the basis of data aggregated across the telmisar-
tan and placebo groups, we performed a test of 
interaction (with a prespecified alpha value of 1%). 
The antiplatelet noninferiority comparison was 
then conducted with a one-sided alpha value of 
2.5%; the test of superiority was two-sided with 
an alpha value of 5%. All analyses were performed 
according to the intention-to-treat principle, in-
volved a time-to event approach, and included all 
randomized patients.
Subgroup analyses for the primary outcome 
and for major vascular events were performed for 
prespecified baseline features. These included a 
history of vascular disease, alcohol use, and a 
stroke risk score generated from the overall trial 
data (i.e., age, sex, degree of physical activity, base-
line systolic blood pressure, and history of hyper-
tension, diabetes, myocardial infarction, atrial fi-
brillation, peripheral arterial disease, and stroke 
before the qualifying event).
R esult s
A total of 20,333 patients were enrolled from 695 
centers in 35 countries. One patient who did not 
give written informed consent was randomized 
in error but never received a study drug or under-
went follow-up and was not included in the study 
database. Therefore, the data are reported for 
20,332 patients: 10,181 recipients of aspirin plus 
extended-release dipyridamole and 10,151 recipi-
ents of clopidogrel. The trial commenced on Sep-
tember 11, 2003, and patients were followed un-
til the end of the trial on February 8, 2008. The 
mean duration of follow-up was 2.5 years (range, 
1.5 to 4.4); 1495 patients (7.4%) died during the 
study and 125 patients (0.6% in each treatment 
group) were lost to follow-up.
Baseline characteristics were balanced across 
the two treatment groups (Table 1). The mean age 
was 66.1 years, and 36.0% were women. Almost 
one quarter of the patients had a history of stroke 
or transient ischemic attack before the index 
stroke; 74.0% had a history of hypertension, 46.7% 
of dyslipidemia, 28.2% of diabetes, and 16.3% of 
ischemic coronary artery disease. The median time 
from the qualifying stroke to randomization was 
15 days, and 39.8% of patients were randomized 
within 10 days after that event. The most frequent 
type of ischemic stroke was small-artery occlusion 
(lacune), in 52.0% of patients, whereas 28.6% had 
large-artery atherosclerosis.
Premature discontinuation of the study drug 
was significantly more frequent among patients 
receiving aspirin plus extended-release dipyrida-
mole (2961 patients [29.1%]) than among those 
receiving clopidogrel (2290 [22.6%], P<0.001). 
Medication compliance, defined as taking the 
study medication more than 75% of the time, was 
greater in the clopidogrel group (76.8%) than in 
the group receiving aspirin and extended-release 
dipyridamole (69.6%).
Primary Outcome
Confirmed first recurrence of stroke occurred in 
1814 patients. There was no interaction between 
the treatment benefit of the antiplatelet treatment 
and telmisartan (P = 0.35). The primary outcome 
of first recurrence of stroke occurred in 916 re-
cipients (9.0%) of aspirin plus extended-release 
dipyridamole and 898 recipients (8.8%) of clopid-
ogrel (hazard ratio, 1.01; 95% CI, 0.92 to 1.11) 
(Table 2 and Fig. 1A). Although the hazard ratio 
is very close to 1.00 (representing equivalence), 
the upper limit of the confidence interval ex-
tends beyond the prespecified noninferiority mar-
gin of 1.075.
Ischemic stroke accounted for 87.4% (1585 of 
1814) of the recurrent strokes (Fig. 2). Although 
there were 25 fewer ischemic recurrent strokes in 
the group receiving aspirin plus extended-release 
dipyridamole than in the group receiving clopid-
ogrel, recipients of aspirin and extended-release 
dipyridamole had 5 more recurrent strokes of 
other or unknown causes and 38 more hemor-
rhagic strokes. Despite this excess of hemorrhagic 
strokes, the number of patients with fatal or dis-
abling strokes (defined by a score of ≥3 on the 
modified Rankin scale at 3 months after the re-
currence of stroke) was similar in the two groups: 
413 (4.1%) in the aspirin–extended-release dipy-
rid amole group and 392 (3.9%) in the clopid o-
grel group (hazard ratio, 1.05; 95% CI, 0.96 to 
1.16). In analyses based on the treatment re-
ceived, the results for the primary outcome were 
virtually the same in the two groups, with recur-
rent stroke occurring in 777 patients (7.6%) receiv-
ing aspirin plus extended-release dipyridamole and 
in 777 patients (7.7%) receiving clo pid o grel (haz-
ard ratio, 1.07; 95% CI, 0.97 to 1.18).
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Table 1. Baseline Characteristics of the Two Treatment Groups.*
Characteristic
Aspirin–ERDP 
(N = 10,181)
Clopidogrel 
(N = 10,151)
Age (yr) 66.1±8.6 66.2±8.5
Female sex (%) 35.9 36.0
Region (%)
Asia 31.8 31.7
Europe, Israel, or Australia 38.1 38.4
Latin America or South Africa 5.6 5.6
United States or Canada 24.5 24.2
Ethnic group (%)†
African 4.0 4.1
Chinese 18.1 17.9
South Asian 8.3 8.5
Other Asian 6.2 6.4
White/European 57.7 57.3
Native Latin 4.9 4.9
Other 0.8 0.9
BMI‡ 26.8±5.0 26.8±5.0
Waist circumference (cm) 96.2±14.1 96.7±14.0
Tobacco use (%)
Never 42.5 42.8
Currently 21.3 21.0
Previously 36.2 36.1
Alcohol use (%)
No regular consumption 64.4 64.9
1–14 drinks/wk 29.6 29.2
15+ drinks/wk 5.4 5.2
Obesity (%)§ 25.4 25.9
Exercise category (%)
Sedentary 35.6 35.7
Some physical activity 31.9 31.8
Intense physical activity 32.0 31.8
Time from qualifying stroke to randomization
Median (days) 15 15
≤10 days (%) 39.6 40.0
11–30 days (%) 29.1 28.8
31–90 days (%) 27.7 27.5
>90 days (%) 3.3 3.5
TOAST classification of qualifying stroke (%)
Large-artery atherosclerosis 28.8 28.3
Cardioembolism 1.8 1.8
Small-artery occlusion (lacune) 52.0 52.1
Acute stroke of other determined cause 2.0 2.1
Stroke of undetermined cause 15.4 15.6
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Secondary and Tertiary Outcomes
The numbers of patients with the secondary out-
come of stroke, myocardial infarction, or death 
from vascular causes were identical in the two 
groups: 1333 patients (13.1%) (hazard ratio for as-
pirin plus extended-release dipyridamole vs. clopi-
dogrel, 0.99; 95% CI, 0.92 to 1.07) (Table 2 and 
Fig. 1B). The rates of most tertiary (efficacy) out-
comes were similar in the two groups (Table 2). 
The rate of new or worsening congestive heart fail-
ure was significantly lower in the group receiving 
aspirin plus extended-release dipyridamole (144 pa-
tients [1.4%]) than in the group receiving clopi-
dogrel (182 patients [1.8%]; hazard ratio, 0.78; 
95% CI, 0.62 to 0.96). There was no significant 
difference in the rate of recurrent stroke or major 
hemorrhagic event between the recipients of as-
pirin plus extended-release dipyridamole (1194 
[11.7%]) and the recipients of clopidogrel (1156 
[11.4%]; hazard ratio, 1.03; 95% CI, 0.95 to 1.11). 
Our post hoc analysis comparing the rates of the 
secondary outcome or major hemorrhage, like that 
Table 1. (Continued.)
Characteristic
Aspirin–ERDP 
(N = 10,181)
Clopidogrel 
(N = 10,151)
Score on modified Rankin scale (%)¶
0 13.9 14.1
1 37.3 37.3
2 24.9 25.1
3–5 23.9 23.5
Baseline NIHSS score (%)‖
0–1 39.6 40.0
2–3 29.3 29.6
4–5 16.7 16.3
6–14 13.6 13.5
>14 0.8 0.7
Previous stroke or TIA (%) 24.2 24.9
Previous stroke 18.1 18.4
TIA 8.6 8.8
Atherosclerotic disease (%) 19.3 19.5
MI 6.7 6.7
Ischemic coronary artery disease 16.1 16.4
PAOD 2.9 3.0
CHF (%) 2.6 2.6
Hypertension (%) 74.4 73.6
Diabetes mellitus (%) 28.5 28.0
Hyperlipidemia (%) 46.5 46.8
Atrial fibrillation (%) 2.7 2.6
Valvular disease (%) 1.7 1.7
Deep-vein thrombosis (%) 1.5 1.5
* Plus–minus values are means ±SD. P values for all comparisons between the two groups were greater than 0.05 except 
for waist circumference, for which P = 0.02. CHF denotes congestive heart failure, ERDP extended-release dipyridamole, 
MI myocardial infarction, PAOD peripheral arterial obstructive disease, TIA transient ischemic attack, and TOAST Trial 
of Org 10172 in Acute Stroke Treatment.
† Ethnic group was self-reported. The term Native Latin refers to Latin American ethnic background. 
‡ The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.
§ Obesity was defined as a BMI of 27 or more for Asian patients and 30 or more for all others.
¶ Scores on the modified Rankin scale ranged from 0 to 5, with higher scores indicating greater disability. 
‖ Higher scores on the National Institutes of Health Stroke Scale (NIHSS) indicate worse stroke severity.
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performed in the European/Australasian Stroke 
Prevention in Reversible Ischemia Trial (ESPRIT; 
ClinicalTrials.gov number, NCT00161070)10 showed 
no differences between the two groups (1572 pa-
tients [15.4%] receiving aspirin plus extended-
release dipyridamole and 1563 patients [15.4%] 
receiving clopidogrel; hazard ratio, 1.00; 95% CI, 
0.93 to 1.07).
Subgroup Analyses
The relative difference with regard to the primary 
outcome of first recurrence of stroke between the 
Table 2. Hazard Ratios for Primary, Secondary, and Key Tertiary Efficacy and Safety Outcomes.*
Outcome
Aspirin–ERDP 
(N = 10,181)
Clopidogrel 
(N = 10,151)
Hazard Ratio  
for Aspirin–ERDP  
(95% CI)
number (percent)
Primary outcome: recurrent stroke 916 (9.0) 898 (8.8) 1.01 (0.92–1.11)
Secondary outcome: composite of vascular events (stroke, MI,  
or death from vascular causes)
1333 (13.1) 1333 (13.1) 0.99 (0.92–1.07)
Tertiary outcome
MI 178 (1.7) 197 (1.9) 0.90 (0.73–1.10)
Death from vascular causes 435 (4.3) 459 (4.5) 0.94 (0.82–1.07)
Death from any cause 739 (7.3) 756 (7.4) 0.97 (0.87–1.07)
New or worsening CHF† 144 (1.4) 182 (1.8) 0.78 (0.62–0.96)
Other vascular event 533 (5.2) 517 (5.1) 1.03 (0.91–1.16)
First ischemic stroke‡ 789 (7.7) 807 (7.9) 0.97 (0.88–1.07)
First recurrence of stroke or major hemorrhagic event 1194 (11.7) 1156 (11.4) 1.03 (0.95–1.11)
Safety outcome
Major hemorrhagic event§ 419 (4.1) 365 (3.6) 1.15 (1.00–1.32)
Life-threatening 128 (1.3) 116 (1.1)
Non–life-threatening 291 (2.9) 249 (2.5)
Hemorrhagic event (minor or major)¶ 535 (5.3) 494 (4.9) 1.08 (0.96–1.22)
Intracranial hemorrhage‖ 147 (1.4) 103 (1.0) 1.42 (1.11–1.83)
Intracerebral hemorrhage (hemorrhagic stroke) 90 (0.9) 55 (0.5)
Fatal 28 (0.3) 29 (0.3)
Nonfatal 62 (0.6) 26 (0.3)
Intraocular hemorrhage 22 (0.2) 22 (0.2)
Nonstroke intracranial hemorrhage 35 (0.3) 26 (0.3)
TTP or neutropenia 7 (0.1) 8 (0.1) 0.89 (0.32–2.44)
* Covariates in the Cox model were baseline values for age, use or nonuse of angiotensin-converting–enzyme inhibitor, score on the modified 
Rankin scale, and baseline diabetes status. Differences between the treatment groups were not significant unless otherwise stated. CHF  
denotes congestive heart failure, ERDP extended-release dipyridamole, MI myocardial infarction, and TTP thrombotic thrombocytopenic 
purpura.
† P = 0.02 for the hazard ratio for CHF.
‡ Data on first ischemic stroke are from the 780 patients in the aspirin–ERDP group and the 805 patients in the clopidogrel group, with a 
stroke contributing to the primary outcome, plus 9 more and 2 more patients, respectively, with an ischemic stroke.
§ Major hemorrhagic event (life-threatening or non–life-threatening) was defined as a hemorrhagic event that resulted in clinically significant 
disability, symptomatic intracranial hemorrhage, intraocular bleeding causing loss of vision, the need for a transfusion of 2 or more units of 
red cells or the equivalent amount of whole blood, or the need for hospitalization. Life-threatening hemorrhagic events were defined as 
those that were fatal or that required use of intravenous inotropic medication to maintain blood pressure, surgical intervention, or transfu-
sion of 4 or more units of red cells or the equivalent amount of whole blood. Non–life-threatening hemorrhagic events were defined as 
those classified as major hemorrhagic events but not as life-threatening.
¶ All hemorrhagic events leading to interruption of therapy were classified as such by the investigator. Bleeding events related to surgical pro-
cedures were classified as hemorrhagic events. Bleeding events due to accidental trauma were not classified as hemorrhagic events.
‖ P = 0.006 for the hazard ratio for intracranial hemorrhage.
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Figure 1. Kaplan–Meier Estimates of the Cumulative Probability of Primary 
and Secondary Outcomes, According to Treatment Group.
The primary outcome of first recurrence of stroke (Panel A) occurred in 916 
of 10,181 patients (9.0%) treated with aspirin plus extended-release dipyrid-
amole (ERDP) and in 898 of 10,151 patients (8.8%) treated with clopidogrel 
(hazard ratio for aspirin–ERDP, 1.01; 95% confidence interval [CI], 0.92 to 
1.11). The main secondary outcome of stroke, myocardial infarction (MI), 
or death from vascular causes (Panel B) occurred in 1333 patients (13.1%) 
in each of the two groups (hazard ratio for aspirin–ERDP, 0.99; 95% CI, 
0.92 to 1.07). The estimated haz rd ratios are based on a Cox model with 
covariates of baseline values of age, use or nonuse of angiotensin-convert-
ing–enzyme inhibitors, diabetes status, and score on the modified Rankin 
scale.
group receiving aspirin plus extended-release dipy-
ridamole and the clopidogrel group was consistent 
across multiple prespecified and exploratory sub-
groups based on baseline characteristics (Fig. 3).
Safety Outcomes
Major hemorrhagic events occurred more frequent-
ly among recipients of aspirin plus extended-release 
dipyridamole (419 patients [4.1%]) than among 
recipients of clopidogrel (365 patients [3.6%]; haz-
ard ratio, 1.15; 95% CI, 1.00 to 1.32). Intracra-
nial hemorrhage (including the 128 hemorrhagic 
strokes counted in the primary outcome) were sig-
nificantly more frequent in patients receiving as-
pirin plus extended-release dipyridamole (147 
patients [1.4%], vs. 103 patients receiving clo pid-
o grel [1.0%]; hazard ratio, 1.42; 95% CI, 1.11 to 
1.83). There were no significant differences be-
tween the two groups in the frequency of death, 
any hemorrhagic event (major or minor), or throm-
botic thrombocytopenic purpura or neutropenia 
(Table 2). The most commonly reported serious 
adverse events (in at least 0.4% of patients) are 
reported in the Supplementary Appendix.
Adverse events leading to permanent discon-
tinuation of the study medication were increased 
in the group receiving aspirin plus extended-release 
dipyridamole (1650 patients [16.4%]) as compared 
with the group receiving clopidogrel (1069 patients 
[10.6%]). Discontinuations due to adverse events 
occurred earlier with aspirin plus extended-release 
dipyridamole, with 49.6% of all such discontinu-
ations occurring within the first 2 months as 
compared with 32.5% of those in the clopidogrel 
group. Permanent discontinuation of study med-
ication due to headache was more frequent among 
recipients of aspirin plus extended-release dipy-
rid amole (593 [5.9%]) than among recipients of 
clopidogrel (87 [0.9%]). Headache also occurred 
more frequently in the group receiving aspirin and 
extended-release dipyridamole (30.2% of patients 
by day 7, vs. 10.2% in the group receiving clo pid-
o grel). Incidence rates for selected adverse events 
leading to discontinuation are listed in Table 3 
(with all occurring in at least 0.1% of patients re-
ported in the Supplementary Appendix).
Discussion
The PRoFESS trial provides important evidence re-
garding the direct comparison of two antiplatelet 
agents after noncardioembolic stroke. All anti-
platelet agents tested in this trial were already 
approved for the prevention of recurrent stroke in 
most of the participating countries. The trial did 
not meet the predefined statistical criteria for non-
inferiority, but it showed similar rates of recurrent 
stroke in the group receiving aspirin and extended-
release dipyridamole and in the group receiving 
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clopidogrel. Therefore, the study does not show 
that either aspirin plus extended-release dipyrida-
mole or clopidogrel is superior to the other in the 
prevention of recurrent stroke.
There were more hemorrhagic strokes with as-
pirin plus extended-release dipyridamole than with 
clopidogrel. However, there was no significant dif-
ference in the risk of fatal or disabling stroke. Al-
though indirect evidence from previous random-
ized trials with aspirin as a comparison drug had 
suggested that aspirin plus extended-release dipy-
rid amole was more effective than clopidogrel for 
the prevention of stroke recurrence, direct com-
parisons within a randomized trial are the most 
valid estimates of comparative treatment effica-
cy. The trial results emphasize the need for direct 
comparisons between active antiplatelet agents in 
the context of prevention of recurrent stroke. In-
direct comparisons are limited by differences 
in antiplatelet trial designs, populations of pa-
tients, choice of drugs to compare with aspirin, 
and definitions of the primary outcomes.24
Despite similar rates of recurrent stroke in our 
two treatment groups, we were not able to make a 
claim of noninferiority. The trial was designed to 
demonstrate the superiority of aspirin plus ex-
tended-release dipyridamole, assuming a 13% 
relative risk reduction with 82% power. Given 
the uncertainty about indirect comparisons, we 
added a noninferiority test with a conservative 
delta value as a precursor to the superiority test. 
Power calculations showed that the trial would 
have a statistical power of 82% to show noninfe-
riority if the relative risk reduction for aspirin 
plus extended-release dipyridamole as compared 
with clopidogrel was only 6.5%. Given equivalent 
efficacies of the two treatments, the trial was 
substantially underpowered (with only 30% pow-
er) to show noninferiority. Furthermore, we chose 
a very conservative noninferiority margin of 
7.5%. Although some statistical guidelines for 
the derivation of a noninferiority margin have 
been published,25-27 the choice of margin is still 
controversial.28,29 If noninferiority is declared, 
then the clinician may conclude that one treat-
ment is as good as or better than the other. If 
noninferiority is not found, the clinician cannot 
be confident, within the specified noninferiority 
margin, that the treatment of interest is at least 
as good as the other. Nor can the clinician con-
clude that the comparison treatment is noninfe-
rior to or better than the treatment of interest.
The rates of the composite outcome of stroke, 
myocardial infarction, or death from vascular 
causes were identical in the two treatment groups, 
with narrow confidence intervals, suggesting that 
there is little likelihood for a clinically important 
difference between the two regimens with regard 
to these events. The rates of primary and second-
ary outcomes were consistent across multiple base-
line risk factors. Our trial adds to the evidence that 
recurrent stroke is the most frequent vascular event 
among survivors of stroke. Randomized trials in-
volving aspirin added to clopidogrel as compared 
with aspirin alone have suggested stronger effects 
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Figure 2. Frequency of Types of Recurrent Stroke 
among the Study Patients, According to Treatment 
Group.
The mean follow-up period was 2.5 years. Numbers of 
patients in each stroke category are given to the right 
of the bar and total numbers are given on top. The haz-
ard ratio for recurrent stroke among patients receiving 
aspirin plus extended-release dipyridamole (ERDP), as 
compared with those receiving clopidogrel, was 1.01 
(95% confidence inte val, 0.92 to 1.11).
Figure 3 (facing page). Hazard Ratios for the Primary 
Outcome of First Recurrence of Stroke, According to 
Prespecified and Post Hoc Baseline Characteristics.
The hazard ratios are for recurrent stroke among pa-
tients receiving aspirin plus extended-release dipyrida-
mole (ERDP) as compared with those receiving clopid-
ogrel. The sizes of the squares are proportional to the 
number of events. All tests for interaction between 
treatment group and subgroup had P values greater 
than 0.05, except for history of hypertension, for which 
P = 0.05. See the Supplementary Appendix for the cal-
culation of stroke risk score. Ethnic group was self- 
reported. ACE denotes angiotensin-converting enzyme, 
TIA transient ischemic event, and TOAST Trial of Org 
10172 in Acute Stroke Treatment.
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of the combination for reducing the composite 
end point of stroke, myocardial infarction, or 
death from vascular causes — particularly among 
patients with acute coronary syndromes15 — and 
some have questioned the efficacy of aspirin plus 
extended-release dipyridamole in the prevention 
of myocardial infarction. Our trial results show 
that therapy with aspirin plus extended-release 
dipyridamole and therapy with clopidogrel have 
similar effects on reduction of the composite of 
vascular events after stroke, including myocardial 
infarction.
The trial showed no significant difference in 
the tertiary outcome of first recurrence of stroke 
or major hemorrhagic event, but there was an in-
creased risk of intracranial bleeding (including in-
tracerebral hemorrhages, 128 of which were also 
counted toward the primary outcome of recurrent 
stroke) among patients treated with aspirin plus 
extended-release dipyridamole, as compared with 
patients treated with clopidogrel. Trials of clo-
pid ogrel plus aspirin have shown greater risks of 
life-threatening bleeding as compared with mono-
therapy.8,16 In both the European Stroke Prevention 
Study 2 (ESPS2) and ESPRIT, there was no signifi-
cant increase in the risk of major hemorrhage in 
the aspirin-plus-dipyridamole group as compared 
with the aspirin group.5,10,11
The rates of permanent discontinuation of 
study treatment due to headache were much lower 
in this study than in previous trials, probably ow-
ing to counseling of patients and the option to 
adjust the dose over a period of days if necessary. 
Despite this finding, there was a difference in the 
rates of discontinuation, with more recipients of 
aspirin plus extended-release dipyridamole than 
recipients of clopidogrel stopping early.
A significant reduction in the risk of new or 
worsening congestive heart failure was found with 
aspirin plus extended-release dipyridamole as com-
pared with clopidogrel. The explanation for this 
finding is not known, but it may relate to an in-
crease in adenosine level and augmentation of 
coronary collateralization.30
The PRoFESS trial showed that, among patients 
with a noncardioembolic ischemic stroke, the risks 
of recurrent stroke or the composite of stroke, 
myocardial infarction, or death from vascular 
causes are similar with aspirin plus extended-
release dipyridamole and with clopidogrel. Despite 
the increased risk of hemorrhagic strokes with 
aspirin plus extended-release dipyridamole as com-
pared with clopidogrel, the net benefit with re-
gard to the risk of recurrent stroke or major hem-
orrhagic event was similar in the two groups. 
Furthermore, there was no significant difference 
between the two treatments in the risk of fatal or 
disabling strokes. The large number and interna-
tional representation of patients, who were from 
35 countries or regions, enhances the generaliz-
ability of our findings. These findings provide 
additional safety and efficacy data physicians need 
in making individual treatment decisions for pre-
vention of recurrent stroke or the combined end 
point of stroke, myocardial infarction, or death 
from vascular causes in their patients with stroke.
Supported by Boehringer Ingelheim (which manufactures Ag-
grenox, a combination of extended-release dipyridamole [200 mg] 
and aspirin [25 mg], and Micardis [telmisartan, 80 mg]). In se-
lected countries, the telmisartan comparison of the PRoFESS study 
was supported by Bayer Schering Pharma and GlaxoSmith Kline.
Table 3. Incidence of Selected Adverse Events Leading to Permanent Discontinuation of Study Medications.*
Variable Aspirin–ERDP Clopidogrel
number (percent)
Patients receiving antiplatelet medication 10,055 (100.0) 10,040 (100.0)
Patients with adverse events leading to treatment discontinuation 1,650 (16.4) 1,069 (10.6)
Headache 593 (5.9) 87 (0.9)
Vomiting 158 (1.6) 37 (0.4)
Nausea 155 (1.5) 58 (0.6)
Dizziness 134 (1.3) 52 (0.5)
Atrial fibrillation 122 (1.2) 143 (1.4)
Diarrhea 102 (1.0) 42 (0.4)
Hypotension 54 (0.5) 35 (0.3)
* ERDP denotes extended-release dipyridamole.
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